The Demand for Autoinjectors

The SafeClickTM is the worlds most advanced disposable autoinjector for pre-filled syringes, offering a solution to all regulatory, clinical, marketing, anticounterfeit and tampering needs, whilst offering patients and healthcare providers the optimal solution for self-treatment and reduction of reliance on healthcare provision. We have one of only a handful of devices able to cope with viscous in addition to non-viscous drugs and the only one to have the additional needlestick and safety features incorporated into our cost-effective and reliable device.

Several factors have newly arisen which will now lead to a massive expansion in the need for more advanced autoinjectors in the next 4 years.

  • With 5% of the population having an Autoimmune disease (WHO) and the realisation by clinicians and patients that new drug categories offer a chance of cure and disease modulation rather than simply modifying the symptoms, there will be an explosion in the demand and need for viscous biologics.
  • 2/3 of new drugs set to launch in the next 4 years are biologic and sustained release drugs that are so thick and viscous, that auto-injectors offer the only realistic way for patients to self-inject. There are more biologic drugs in development than traditional drugs.
  • The marketing advantages gained by access to leading auto-injector technology makes them a "must have" for Pharma companies who want to have a presence in the biologics market.
  • Federal Regulations in the USA, EU and Australia that mandate the prevention of needle-stick injuries, with autoinjectors singled out as the most effective method of risk prevention (88% redn). New global regulation that requires active needle protection to prevent needle-stick injury rendering passive needle safeties and external plastic needle-shields obsolete.
  • The opportunity to extend the pharmaceutical product lifecycle. extending the patent life of injectable drugs allowing brand extension and the maintenance of a high margin on the sale of a pharmaceutical product reaching the end of its patent life.
  • The realisation by healthcare providers that auto-injectors allow inexpensive home medication and decreased time out of the workplace rather than expensive and time consuming in/out-patient care.
  • The exponential growth in the use of pre-filled syringes due to regulatory and safety concerns (2.4 bn units pa in Europe alone) will lead to the need for more auto-injectors.
  • New classes of drugs where safe accurate drug delivery to exact depths in the skin/muscle is paramount and can only be accomplished by auto-injectors.
  • Double digit growth in auto-injectors for established pharma such as Anaphlyaxis, EPO, somatomedins, FSH.
  • Pandemic and NGO requirements for rapid access self-injections without depletion of healthcare resources.
  • Military/NGO requirements for analgesia/nerve/biological/vaccine agent's self-administration. NGO's , Defence and Pandemic management and planning have realized the opportunities for easy self-administration coupled with the possibilities of easy and safe mass distribution via non-medical pathways.
  • 22% incidence of needle-phobia inhibiting usage of injectables.
  • The protection of patent-expired pharmaceutical products, i.e. extension of drug life-cycle.
  • Anti-counterfeit and tampering regulation.
  • Enhanced patient compliance and safety with auto-injection.

Drug categories where imminent release of Biologics includes the following categories;

  • Rheumatological Diseases
  • Inflammatory Bowel disease
  • Autoimmune Systemic therapy
  • Transplant modulation
  • Anaphylaxis
  • Military; nerve agent/chemical
  • Seronegative Arthritides
  • Growth Hormone
  • Psychiatric
  • Contraception
  • Hepatitis
  • Haematopoietic
  • Vaccinations of which there will be innumerate possibilities
  • Multiple Sclerosis
  • Migraine
  • Interferon
  • Therapeutic Peptides
  • Infertility